Humanwell Healthcare Group Co Ltd
SSE:600079
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Humanwell Healthcare Group Co Ltd
SSE:600079
|
30B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Humanwell Healthcare Group Co Ltd
Glance View
In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Humanwell Healthcare Group Co Ltd is 5.9%, which is below its 3-year median of 7.4%.
Over the last 3 years, Humanwell Healthcare Group Co Ltd’s Net Margin has decreased from 9.8% to 5.9%. During this period, it reached a low of 5.2% on Dec 31, 2024 and a high of 11.1% on Dec 31, 2022.